CARIBOU BIOSCIENCES, INC. (NASDAQ: CRBU) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Caribou Biosciences, Inc. (NASDAQ: CRBU)
06 mars 2023 01h45 HE
|
Bernstein Liebhard LLP
Did you lose money on investments in Caribou Biosciences? If so, please visit Caribou Biosciences, Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212)...
CARIBOU BIOSCIENCES, INC. (NASDAQ: CRBU) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Caribou Biosciences, Inc. (NASDAQ: CRBU)
14 févr. 2023 16h00 HE
|
Bernstein Liebhard LLP
Did you lose money on investments in Caribou Biosciences? If so, please visit Caribou Biosciences, Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212)...
CRBU Class Action Lawsuit Announced: Johnson Fistel Encourages Shareholders to Submit Their Caribou Biosciences Information
11 févr. 2023 11h02 HE
|
Johnson Fistel, LLP
SAN DIEGO, Feb. 11, 2023 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Caribou Biosciences, Inc....
Lawsuit filed for Investors with substantial Losses in Caribou Biosciences, Inc. (NASDAQ: CRBU) shares announced by the Shareholders Foundation
10 févr. 2023 22h36 HE
|
Shareholders Foundation, Inc.
SAN DIEGO, Feb. 10, 2023 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain investors in Caribou Biosciences, Inc. (NASDAQ: CRBU) shares. Investors...
Caribou Biosciences to Participate in Upcoming Investor Conferences
01 févr. 2023 16h05 HE
|
Caribou Biosciences, Inc.
BERKELEY, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel...
Caribou Biosciences to Present at 41st Annual J.P. Morgan Healthcare Conference
03 janv. 2023 16h05 HE
|
Caribou Biosciences, Inc.
BERKELEY, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel...
Caribou Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update
08 nov. 2022 16h00 HE
|
Caribou Biosciences, Inc.
-- CB-010 ANTLER Phase 1 trial in r/r B-NHL advancing; additional data from cohort 1 expected by YE 2022 -- -- CB-011 IND application for r/r MM submitted to FDA in Q4 2022 -- -- Strong...
Caribou Biosciences Presents Case Report on Long-term Follow up of First Patient Dosed in Phase 1 ANTLER Trial at the Lymphoma, Leukemia, & Myeloma Congress 2022
18 oct. 2022 09h00 HE
|
Caribou Biosciences, Inc.
BERKELEY, Calif., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the...
Caribou Biosciences Reports Positive Additional Data from CB-010 Allogeneic CAR-T Cell Therapy Phase 1 ANTLER Trial at the European Hematology Association (EHA) 2022 Hybrid Congress
10 juin 2022 03h00 HE
|
Caribou Biosciences, Inc.
-- 100% CR rate (6 of 6 patients), with 40% CR rate (2 of 5 patients) at 6 months, achieved as best response following 1 dose at the initial dose level in patients with aggressive r/r B-NHL -- --...
Caribou Biosciences Announces Webcast Conference Call to Highlight Initial CB-010 ANTLER Phase 1 Data Presentation at EHA on June 10, 2022
01 juin 2022 16h05 HE
|
Caribou Biosciences, Inc.
BERKELEY, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that the...